ADAP Adaptimmune Therapeutics PLC

Price (delayed)

$1.725

Market cap

$279.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$214.48M

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform ...

Highlights
The company's revenue has surged by 156% YoY and by 51% QoQ
Adaptimmune Therapeutics's gross profit has surged by 156% YoY and by 51% QoQ
The company's quick ratio has shrunk by 55% YoY and by 22% QoQ
Adaptimmune Therapeutics's equity has decreased by 47% YoY and by 21% from the previous quarter

Key stats

What are the main financial stats of ADAP
Market
Shares outstanding
162.19M
Market cap
$279.78M
Enterprise value
$214.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.66
Price to sales (P/S)
29.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.09
Earnings
Revenue
$9.29M
EBIT
-$169.47M
EBITDA
-$162.74M
Free cash flow
-$11.67M
Per share
EPS
-$1.08
Free cash flow per share
-$0.07
Book value per share
$1.04
Revenue per share
$0.06
TBVPS
$2.67
Balance sheet
Total assets
$419.8M
Total liabilities
$256.65M
Debt
$25.96M
Equity
$163.15M
Working capital
$293.31M
Liquidity
Debt to equity
0.16
Current ratio
5.43
Quick ratio
4.65
Net debt/EBITDA
0.4
Margins
EBITDA margin
-1,751.8%
Gross margin
100%
Net margin
-1,836.3%
Operating margin
-1,876.6%
Efficiency
Return on assets
-41.8%
Return on equity
-76.8%
Return on invested capital
-57.7%
Return on capital employed
-47.9%
Return on sales
-1,824.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADAP stock price

How has the Adaptimmune Therapeutics stock price performed over time
Intraday
-0.86%
1 week
-0.29%
1 month
13.49%
1 year
-60.71%
YTD
-54%
QTD
-16.26%

Financial performance

How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$9.29M
Gross profit
$9.29M
Operating income
-$174.34M
Net income
-$170.59M
Gross margin
100%
Net margin
-1,836.3%
The company's revenue has surged by 156% YoY and by 51% QoQ
Adaptimmune Therapeutics's gross profit has surged by 156% YoY and by 51% QoQ
The net margin has surged by 52% year-on-year and by 29% since the previous quarter
ADAP's operating margin has soared by 52% YoY and by 29% QoQ

Growth

What is Adaptimmune Therapeutics's growth rate over time

Valuation

What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
1.66
P/S
29.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.09
Adaptimmune Therapeutics's EPS has decreased by 13% YoY and by 6% from the previous quarter
Adaptimmune Therapeutics's equity has decreased by 47% YoY and by 21% from the previous quarter
ADAP's price to book (P/B) is 42% lower than its 5-year quarterly average of 2.9 and 36% lower than its last 4 quarters average of 2.6
The company's revenue has surged by 156% YoY and by 51% QoQ
The P/S is 75% below the 5-year quarterly average of 116.2 and 68% below the last 4 quarters average of 91.6

Efficiency

How efficient is Adaptimmune Therapeutics business performance
The return on equity has dropped by 97% year-on-year and by 25% since the previous quarter
The company's return on invested capital has shrunk by 54% YoY and by 15% QoQ
Adaptimmune Therapeutics's ROS has soared by 52% YoY and by 29% from the previous quarter
Adaptimmune Therapeutics's return on assets has decreased by 39% YoY and by 7% QoQ

Dividends

What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADAP.

Financial health

How did Adaptimmune Therapeutics financials performed over time
ADAP's total assets is 64% greater than its total liabilities
ADAP's total liabilities has soared by 151% YoY but it is down by 2.6% QoQ
The company's quick ratio has shrunk by 55% YoY and by 22% QoQ
The debt is 84% smaller than the equity
ADAP's debt to equity has surged by 129% year-on-year and by 33% since the previous quarter
Adaptimmune Therapeutics's equity has decreased by 47% YoY and by 21% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.